Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24015624 | 0.83 | HTR6 (0.52) | HTR6PTGDR2PTGDRSRCACLY | |
| SCHEMBL25811425 | 0.82 | PTGDR2 (0.47) | HTR6PTGDR2PTGDRSRCACLY | |
| SCHEMBL19605706 | 0.82 | HTR6 (0.50) | HTR6PTGDR2PTGDRSRCCXCL8 | |
| SCHEMBL25811440 | 0.81 | PTGDR2 (0.46) | HTR6PTGDR2PTGDRSRCACLY | |
| SCHEMBL25811430 | 0.80 | PTGDR2 (0.51) | HTR6PTGDR2PTGDRSRCACLY | |
| SCHEMBL25811422 | 0.79 | MAPT (0.57) | HTR6PTGDR2PTGDRSRCNOD1 | |
| SCHEMBL12968247 | 0.77 | BRD4 (0.49) | HTR6SRCACLYCXCL8NOD1 | |
| SCHEMBL25811428 | 0.75 | PTGDR2 (0.52) | PTGDR2PTGDRNOD1 | |
| SCHEMBL30159837 | 0.73 | PCSK9 (0.57) | HTR6CXCL8NOD1 | |
| SCHEMBL26104217 | 0.73 | PCSK9 (0.57) | HTR6CXCL8NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | HTR6 14/4885PTGDR2 4166/4885PTGDR 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.